A Phase 1 Study to Compare the Pharmacokinetics of CAL-101 Capsules to Tablets in Healthy Male Subjects.

Completed

• Conditions: Blooddisease; leukemia/lymophoma; 10047954

• Registration Number: NL-OMON35094
• Lead Sponsor: Calistoga Pharmaceuticals Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 15

Inclusion Criteria

- healthy male volunteers
- age between 18 and 65 years (inclusive)
- BMI between 18 and 30 kg/m2
- non heavy or average smoker
- at screening the state of health satisfies the entry requirements

Exclusion Criteria

Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor (500 mL or more) within 90 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Safety , Pharmacokinetics</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>N/A</p><br>